1.
Nishimura J- ichi, Ando K, Masuko M, Noji H, Ito Y, Mayer J, Griskevicius L, Bucher C, Müllershausen F, Gergely P, Rozenberg I, Schubart A, Chawla R, Rondeau J-M, Roguska M, Splawski I, Keating MT, Johnson L, Danekula R, Bagger M, Watanabe Y, Haraldsson B, Kanakura Y. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. haematol [Internet]. 2022Mar.10 [cited 2022Jun.30];107(6):1483-8. Available from: https://haematologica.org/article/view/haematol.2020.265868